DoubleDown Interactive Co. (DDI) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Company Participants Richard Land - Investor Relations AdvisorIn Keuk Kim - Chief Executive OfficerJoseph A. Sigrist - CFO & Director Conference Call Participants Aaron Lee - Senior Research AnalystJosh Nichols - Senior Research AnalystGreg Gibas - Vice President & Senior Research Analyst Operator Good afternoon, and welcome to Double Down Interactive Earnings Conference Call for the First Quarter Ended 03/31/2025. My name is Mi ...

DoubleDown Interactive Co. (DDI) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Company Participants Richard Land - Investor Relations AdvisorIn Keuk Kim - Chief Executive OfficerJoseph A. Sigrist - CFO & Director Conference Call Participants Aaron Lee - Senior Research AnalystJosh Nichols - Senior Research AnalystGreg Gibas - Vice President & Senior Research Analyst Operator Good afternoon, and welcome to Double Down Interactive Earnings Conference Call for the First Quarter Ended 03/31/2025. My name is Mi ...

authID (AUID) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Company Participants Graham Arad - General CounselRhon Daguro - CEO & DirectorEd Sellitto - Chief Financial OfficerGary Brode - Founder Conference Call Participants None - Analyst Operator First Quarter twenty twenty five Financial Results. After the speakers' presentation, there will be a question and answer session. If your question has been answered and you'd like to remove yourself from the queue, simply press 11 again. As a reminder, today's ...

Allogene Therapeutics (ALLO) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Company Participants Christine Cassiano - Executive VP, Chief Corporate Affairs & Brand Strategy OfficerDavid Chang - Co-Founder, President, CEO & DirectorZachary Roberts - Executive VP of Research & Development and Chief Medical OfficerGeoffrey Parker - Executive VP & CFOMichael Yee - Managing DirectorMatthew Biegler - Managing DirectorSamantha Semenkow - Vice PresidentReni Benjamin - Managing DirectorCaleb Stubbs - Biotechnology E ...

Urgent.ly (ULY) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 Good afternoon, and welcome to Urgently's First Quarter twenty twenty five Conference Call. As a reminder, today's call is being recorded and your participation implies consent to such recording. At this time, all participants are in a listen only mode. A brief question and answer session will follow the formal presentation. With that, I would like to turn the call over to Ms. Jenny Mitchell, Vice President of Finance Strategy and Inves ...

Surgepays (SURG) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 note this conference is being recorded. I will now turn the conference over to your host, Mike McCormack, Managing Director of Investor Relations at Surg Pace. You may begin. Speaker1 Thank you, operator, and good afternoon, everyone. Welcome to the Surg Pays twenty twenty five First Quarter Financial Results Conference Call. Today's date is 05/13/2025. And on the call today from the company are Brian Cox, President and CEO and Tony Ev ...

Surf Air Mobility (SRFM) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 I would now like to turn the call over to Sam Levinson, Investor Relations. Please go ahead. Speaker1 Thank you, operator. Welcome to Surf Air Mobility's first quarter twenty twenty five earnings call. I'm joined today by Deanna White, Chief Executive Officer and Chief Operating Officer and Oliver Reeves, Chief Financial Officer. Our earnings release can be found on the SEC EDGAR website and on our Surf Air Mobility Investor Re ...

Financial Data and Key Metrics Changes - Research and development revenue for Q1 2025 rose 6% to $6,700,000 from $6,300,000 in Q1 2024, reflecting increased activity under the BARDA Project BioShield contract [12] - Gross margin increased to 47.2% from 46.6% in Q1 2024 due to a higher concentration of direct labor as a component of revenue [12] - General and administrative expenses decreased significantly from $5,100,000 in Q1 2024 to $4,100,000 in Q1 2025, primarily due to a focus on the BARDA contract and cost-cutting measures [12] - Operating loss for Q1 2025 was $896,000 compared to a net loss of $2,100,000 in Q1 2024 [13] - The company reported net income of $2,900,000 in Q1 2025, a significant improvement from a net loss of $3,200,000 in the same quarter last year [13] - Cash and cash equivalents totaled $14,100,000 as of March 31, 2025, up from $5,200,000 on December 31, 2024 [14] Business Line Data and Key Metrics Changes - The company is focused on advancing its DeepView technology and preparing for FDA submission, which is a key milestone for its product line [5][6] - The DeepView Snapshot M handheld device is in development, with two prototypes successfully assembled [9] Market Data and Key Metrics Changes - The company reiterated its revenue guidance for 2025 at approximately $21,500,000, which does not include contributions from sales of the DeepView system in the UK or Australia [14] Company Strategy and Development Direction - The company is transitioning from a research-focused organization to a commercial entity with a well-defined business focus for 2025 and beyond [4] - The primary goal is to achieve FDA de novo classification submission by the end of Q2 2025, which is critical for future growth [5] - The company is also developing its healthcare intellectual property subsidiary, Spectral IP, which is in the SEC registration process for an initial public offering [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the revenue guidance and noted that the first quarter's strong performance reflects efforts to focus on the FDA submission [18][19] - The company has had over 10 pre-submission meetings with the FDA, which have been constructive and supportive [22][23] - Management is optimistic about the prospects for growth and development, emphasizing the importance of the BARDA partnership [40][41] Other Important Information - The company completed a debt financing agreement of up to $15,000,000, with an initial drawdown of $8,500,000, and raised approximately $2,700,000 in equity financing [7][8] - The burn validation study results, which utilized over 340 billion clinically validated data points, demonstrated the effectiveness of the DeepView technology [6] Q&A Session Summary Question: Guidance on revenue expectations - Management indicated that the revenue guidance of $21,500,000 seems reasonable, although they may restate it if performance continues to exceed expectations [18][19] Question: Preparation for FDA submission - Management highlighted a strong relationship with BARDA and noted that they have been working closely with the FDA to de-risk the submission process [22][23] Question: General administrative expenses outlook - Management anticipates general and administrative expenses to remain consistent with Q1 results, focusing on operational efficiencies [32][33] Question: Development of Snapshot M device - Management confirmed that while they are focused on the FDA submission, they are also advancing the development of the Snapshot M device for military use [38][41] Question: Future relationships with the DoD - Management acknowledged the importance of developing relationships with the DoD and emphasized ongoing efforts to improve the Snapshot M device [49][50]

Financial Data and Key Metrics Changes - As of the end of Q1 2025, assets under construction and completed construction reached over $275 million, driven by construction activities in Phoenix, Dallas, and Denver [7] - Revenues increased by 133% year-over-year and 20% sequentially, attributed to the acquisition of the Camarillo Campus [7] - Operating expenses increased moderately, with a notable rise in fuel expenses and startup costs due to increased headcount and full operations at the Camarillo Hangar Campus [10][12] Business Line Data and Key Metrics Changes - The financial results of Sky Harbor Capital, including Houston, Miami, and Nashville campuses, showed flat revenues in recent quarters, with expectations for significant increases in Q2, Q3, and Q4 as new campuses lease up [12] - Operating expenses rose due to onboarding personnel in anticipation of new campus operations [12] Market Data and Key Metrics Changes - The company is expanding its ground lease portfolio, with new leases in Seattle and Portland, and anticipates significant revenue growth from these locations [14][15] - The average rent per square foot has increased from $29.08 to $35.75, representing a 23% increase over the original estimate, with expectations of reaching $40.06 based on recent leases [17][18] Company Strategy and Development Direction - The company is focusing on vertical integration in construction to manage costs, improve build quality, and speed up project timelines [22][24] - The strategy includes a significant ramp-up in development activities, with plans for 23 campuses by the end of 2025 and 16 additional campuses in development [38][47] - The company aims to differentiate itself through a unique bundled real estate and service offering, targeting high-quality construction and operational efficiency [29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow breakeven by the end of 2025 as new campuses ramp up leasing [8] - The company remains optimistic about demand in business aviation, with no significant impacts from macroeconomic uncertainties reported [90] - Management acknowledged concerns about potential competition but emphasized the strength of their site acquisition capabilities and integrated operational model as competitive advantages [60][62] Other Important Information - The company has approximately $97.5 million in cash and U.S. Treasuries, with a focus on short-term investments for future construction [30] - The company is preparing for a debt issuance of $150 million to $175 million to fund new projects, monitoring market conditions closely [56][99] Q&A Session Summary Question: Plans to raise debt this year - The company is preparing for a financing of $150 million to $175 million for upcoming projects, keeping an eye on market conditions [56][57] Question: Competition from operators replicating the model - Management expressed concern about new competition but believes their integrated model and site acquisition expertise provide a sustainable competitive advantage [60][62] Question: Expected interest rate and timing on financing - Interest rates for a bond deal are expected to be around 5.5%, with bank facilities potentially in the SOFR plus 200 area [99][100] Question: Nashville occupancy - Nashville occupancy is reported at 92%, with actual occupancy exceeding 100% due to the nature of semi-private hangars [92][94]

Pixelworks (PXLW) Q1 2025 Earnings Call May 13, 2025 05:00 PM ET Speaker0 a reminder, this conference call is being recorded for replay purposes. I would now like to turn the call over to Brett Perry with Shelton Group Investor Relations. Please go ahead. Speaker1 Thank you, Kevin. Good afternoon, and thank you for joining today's call. With me on the call are Pixelworks' President and CEO, Todd DeBonis and Chief Financial Officer, Haley Amun. The purpose of today's conference call is to supplement the info ...